Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Common Stock Issued
Cash raised by issuing new shares.
Apyx Medical CorporationNASDAQ: APYX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $88K
Q1 FY2026 common stock issued was $88K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $9.63M. Over 3 fiscal years it compounded at +196.8% a year.
Context
- Common stock issued amounted to 18.1% of revenue in FY2025, up 3.5 pp from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $88K or moves back toward the trailing-twelve-month quarterly average of $2.41M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 9.54M USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +245.4%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.54M | +36.3% |
| FY2024 | 2024-12-31 | 7M | +157.5% |
| FY2023 | 2023-12-31 | 2.72M | +644.7% |
| FY2022 | 2022-12-31 | 365K | +444.8% |
| FY2021 | 2021-12-31 | 67K | — |
Common Stock Issued vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 common stock issued of $9.63M is the 4th largest of the 8 companies compared; the peer median is $968K.
- Its year-over-year change of +42.1% is the 4th highest of 5, against a peer median of +149.5%.
- Common stock issued amounts to 17.2% of revenue for APYX, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.09M | +84.1% | +219.0% | 956.1% | |
| LTM Mar 2026 | $33.08M | +548.5% | +1033.3% | — | |
| LTM Mar 2026 | $14.03M | — | — | 19.4% | |
| LTM Mar 2026 | $9.63M | +42.1% | +196.8% | 17.2% | |
| LTM Mar 2026 | $968K | — | — | 2.8% | |
| LTM Mar 2026 | $116K | -99.8% | — | 203.5% | |
| LTM Mar 2026 | $85K | +214.8% | — | 0.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding APYX) | $968K | +149.5% | +626.2% | 11.1% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.